$8.05
2.19% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Stock price

$8.05
+1.88 30.47% 1M
+3.89 93.51% 6M
+4.29 114.10% YTD
+4.38 119.35% 1Y
+3.29 69.12% 3Y
+1.37 20.51% 5Y
-1.50 15.71% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.18 2.19%
ISIN
US21900C3088
Symbol
CRMD
Sector

Key metrics

Market capitalization $459.73m
Enterprise Value $414.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 511.99
P/S ratio (TTM) P/S ratio 567.57
P/B ratio (TTM) P/B ratio 9.85
Revenue growth (TTM) Revenue growth 2,107.40%
Revenue (TTM) Revenue $810.00k
EBIT (operating result TTM) EBIT $-58.14m
Free Cash Flow (TTM) Free Cash Flow $-51.20m
Cash position $45.61m
EPS (TTM) EPS $-0.93
P/E forward 21.66
P/S forward 15.59
EV/Sales forward 14.06
Short interest 18.11%
Show more

Is CorMedix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

CorMedix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a CorMedix Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a CorMedix Inc forecast:

Buy
100%

Financial data from CorMedix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.81 0.81
1,925% 1,925%
100%
- Direct Costs 1.43 1.43
581% 581%
177%
-0.63 -0.63
271% 271%
-78%
- Selling and Administrative Expenses 51 51
108% 108%
6,272%
- Research and Development Expense 6.44 6.44
52% 52%
795%
-58 -58
52% 52%
-7,143%
- Depreciation and Amortization 0.28 0.28
33% 33%
35%
EBIT (Operating Income) EBIT -58 -58
52% 52%
-7,178%
Net Profit -53 -53
44% 44%
-6,558%

In millions USD.

Don't miss a Thing! We will send you all news about CorMedix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CorMedix Inc Stock News

Neutral
GlobeNewsWire
14 days ago
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, be...
Neutral
GlobeNewsWire
18 days ago
BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a global healthcare company for the supply of DefenCath® (taurolidine and heparin) to its facilities in t...
Neutral
Seeking Alpha
about one month ago
CorMedix Inc. (NASDAQ:CRMD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Joe Todisco - CEO Matt David - EVP and CFO Liz Hurlburt - EVP and Chief Clinical Strategy and Operations Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Jason Butler - Citizens JMP Les Sulewski - Truist John Juco - Needham & Company ...
More CorMedix Inc News

Company Profile

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Head office United States
CEO Joseph Todisco
Employees 82
Founded 2006
Website www.cormedix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today